PAPattamukkil Abraham

Pattamukkil Abraham

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Pattamukkil Abraham has a total of 55 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Trends in Tuberculosis Preventive Therapy Prescribing Among People Living with HIV in South Africa, 2005-2022

    by Abigail Lucas, Laura Steiner, Leisha Genade, Abraham Pattamukkil, Bareng A S Nonyane, Jill Owczarzak, Ebrahim Variava, Limakatso Lebina, Jonathan E Golub, Neil A Martinson, et al.

    Background: Tuberculosis preventive therapy (TPT) reduces tuberculosis incidence among people living with HIV (PLHIV), yet uptake has been sub-optimal. We evaluated trends of TPT prescribing among people initiated on antiretroviral therapy (ART). Setting: Thirty-six public sector clinics in South Africa. Methods: We retrospectively analyzed individual-level clinical data abstracted from clinics in the Free State and North West provinces, South Africa. We included PLHIV who initiated ART 2005-2022 and had ≥1 HIV-related clinic visits on or after 15 September 2021. The timing of TPT prescribing was defined by the earliest recorded TPT prescription date as: (1) TPT prescription within ≤6 months, (2) TPT prescription >6 months, or (3) no recorded TPT prescription on or after ART initiation. Results: Among 48,718 ART initiators, 23,168 (47.6%) were prescribed TPT on or after ART initiation; 15,510 (31.8%) were prescribed TPT ≤6 months and 7,658 (15.7%) were prescribed TPT >6 months after ART initiation. Early TPT prescribing increased from 0.7% in the 2005-2010 cohort to 71.3% in 2022 ART initiators, while TPT prescribing >6 months after ART initiation declined from 28.5% in the 2005-2010 cohort to 1.3% among those who initiated ART in 2022. Cumulative TPT prescribing was 29.2% in the 2005-2010 cohort, 34.2% in the 2011-2015 cohort, and 72.6% in the 2022 cohort. Conclusions: Over 2005-2022, TPT prescribing shifted markedly toward initiation near the time of ART initiation, with early prescribing exceeding 70% by 2022. Cumulative prescribing remained low among people from earlier ART cohorts, underscoring the need for targeted catch-up strategies.

  • Open Access

    Tuberculosis comorbidities, multimorbidity and mortality amongst adults in South Africa: A prospective cohort study nested in a trial

    by Greta K. Wood, Rachel L. Byrne, Limakatso Lebina, Eve Worrall, Pattamukkil Abraham, Emily L. Webb, Peter MacPherson, Neil A. Martinson, Tom Wingfield

    Tuberculosis (TB) comorbidities and multimorbidity - the presence of two or more concurrent diseases or health conditions - are major contributors to TB incidence and mortality. We investigated the prevalence and associated mortality of TB comorbidities and multimorbidity in South Africa. We conducted a prospective cohort study of adults ≥15 years with bacteriologically-confirmed pulmonary TB, nested within a trial in two provinces of South Africa. We investigated five TB key comorbidities (HIV, undernutrition, diabetes, smoking and alcohol use), and assessed all-cause mortality over 15 months using Cox regression. TB comorbidity was defined as TB with one comorbidity, and TB multimorbidity as TB with two or more comorbidities. Of 1997 participants, 1896 (95%) had mortality data available at 15 months. Median age was 38 (IQR 29–48) years, 1203/1997 (60%) were male, 86·2% (95% CI 84·6-86·6) had TB comorbidity and 47·5% (45·3-49·7) had TB multimorbidity. TB comorbidity peaked in participants aged 40–49 years (93% [90–95]), was more prevalent in men vs women (90%[88–91] vs 81%[78–84], p < 0·001), and in urban vs rural areas (88%[86–90] vs 84%[81–86], p = 0·005). Mortality was higher for participants with TB multimorbidity with two (16·0%[13·0-18·8], HR 1·88[1·20-2·95], p = 0·006) and three or more (19·9%[14·9-24·6], HR 2·58[1·56-4·24], p < 0·001) TB key comorbidities than those with no comorbidities (11·2%[7·17-15·0]) or TB comorbidity (10·6% [8·32-12·8]). The joint population attributable fraction for the TB key comorbidities on mortality was 60·0% (49·6-69·2%). TB comorbidities and multimorbidity are highly prevalent and significantly associated with mortality. People with TB should be offered screening and management of comorbidities to reduce their risk of death.


  • Open Access

    Cohort profile: the potentially preventable burden of community-acquired pneumonia in South African adults in the era of widespread PCV13 immunisation and antiretroviral therapy roll-out, before and during the COVID-19 pandemic – the multicentre, multimethod PotPrev Study

    by Firdaus Nabeemeeah, Nadia Sabet, Kennedy Otwombe, Khuthadzo Hlongwane, Lebohang M Mlambo, Tumelo Moloantoa, Michelle Wong, Phetho Mangena, Pattamukkil Abraham, Floris Swanepoel, et al.

    Purpose In the setting of an established childhood pneumococcal vaccination programme with immediate initiation and treatment of antiretroviral therapy (ART) for people living with HIV (PLWH), the risk of adult pneumococcal community-acquired pneumonia (CAP) is not recently described. We aimed to investigate CAP incidence, recurrence, mortality, risk factors and microbiology before and during the COVID-19 pandemic. Participants Adults aged ≥18 years were enrolled in three South African provinces from March 2019 to October 2021, with a brief halt during the initial COVID-19 lockdown. The first group, PdCAP, a surveillance cohort, had their data abstracted to estimate the population incidence of physician-diagnosed CAP by counting incident CAP patients presenting to emergency rooms (ER) and mapping them to catchment areas linked to census data. From those admitted to wards from ERs, a prospective cohort (HospCAP) was enrolled and followed up to 1 year after discharge. Microbiology testing was performed and data were abstracted and collected for economic assessments. A third group (StART) of PLWH without respiratory illness at enrolment, attending primary healthcare clinics to initiate or reinitiate ART, was prospectively enrolled and followed. HospCAP and StART participants (totalling 2950 participants) were followed for at least 1 year and assessed for CAP episodes, hospitalisations and mortality. Findings to date Surveillance identified 6546 patients attending ERs with physician-diagnosed CAP; 61/6546 (0.9%) died in the ER. We prospectively enrolled 2000 hospitalised patients with CAP of whom 1079/2000 (54.0%) were PLWH. Overall, 271/2000 (13.6%) hospitalised CAP patients died during their first admission and 298/2000 (14.9%) died during follow-up. Among StART cohort, 18/950 (1.9%) died during follow-up. Future plans Planned analyses include incidence estimates of pneumococcal serotype-specific adult CAP and its recurrence, using Urinary Antigen Detection assay results to model the burden of pneumococcal CAP better and health economics analyses.


  • Open Access

    The Use of Xpert MTB/Rif for Active Case Finding among TB Contacts in North West Province, South Africa

    by Limakatso Lebina, Nigel Fuller, Tolu Osoba, Lesley Scott, Katlego Motlhaoleng, Modiehi Rakgokong, Pattamukkil Abraham, Ebrahim Variava, Neil Alexander Martinson

    Introduction.Tuberculosis is a major cause of morbidity and mortality especially in high HIV burden settings. Active case finding is one strategy to potentially reduce TB disease burden. Xpert MTB/Rif has recently been recommended for diagnosis of TB.Methods.Pragmatic randomized trial to compare diagnosis rate and turnaround time for laboratory testing for Xpert MTB/Rif with TB microscopy and culture in household contacts of patients recently diagnosed with TB.Results.2464 household contacts enrolled into the study from 768 active TB index cases. 1068 (44%) were unable to give sputum, but 24 of these were already on TB treatment. 863 (53%) participants sputum samples were tested with smear and culture and 2.7% (23/863; CI: 1.62–3.78) were diagnosed with active TB. Xpert MTB/Rif was used in 515 (21%) participants; active TB was diagnosed in 1.6% (8/515; CI: 0.52–2.68).Discussion and Conclusions.Additional 31 cases were diagnosed with contact tracing of household members. When Xpert MTB/Rif is compared with culture, there is no significant difference in diagnostic yield.


  • Latent tuberculous infection in schoolchildren and contact tracing in Matlosana, North West Province, South Africa

    by L. Lebina, P. M. Abraham, M. Milovanovic, K. Motlhaoleng, R. E. Chaisson, M. Rakgokong, J. Golub, E. Variava, N. A. Martinson

    This is a cross-sectional study to estimate the prevalence of latent tuberculous infection (LTBI) and the annual risk of tuberculous infection (ARTI) among a sample of children aged 5 and 7 years in Matlosana, South Africa. LTBI prevalence was significantly higher in children aged 7 years (n = 704) (19.7%, 95%CI 16.75–22.65) than in those aged 5 years (212/1401, 15.1%, 95%CI 13.23–16.97) (P = 0.0075). The ARI was 2.9% (95%CI 2.2–3.6).


  • The use of decentralized GeneXpert by trained non-laboratory technicians in rural clinics in South Africa

    by L. Lebina, P.M. Abraham, K. Motlhaoleng, M. Rakgokong, E. Variava, N.A. Martinson